ASH 2023 | A pro-inflammatory state & peak cytokines are associated with ide-cel toxicity & responses in MM
Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, shares details of a study investigating the association of pre-treatment bone marrow composition and serum cytokine levels with treatment-related toxicities and early responses in patients with triple-class exposed relapsed/refractory (R/R) multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel). Understanding the relationship between these factors may inform toxicity prevention and therapeutic optimization when treating patients with this CAR T-cell therapy. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Bristol Myers Squibb, Karyopharm, Janssen, Pfizer; Membership on an entity’s Board of Directors or advisory committees: Bristol Myers Squibb, Pfizer; Research Funding: Bristol Myers Squibb, Karyopharm, International Myeloma Society Young Investigator Award, Pentecost Family Myeloma Research Center; Honoraria: OncLive, Survivorship
